Wolters Kluwer unveils generative AI Labs for UpToDate
Wolters Kluwer Health to demonstrate initial generative AI application at HLTH 2023 WALTHAM, Mass.–(BUSINESS WIRE)–Wolters…
News
Emplifi Helps Freshpet Streamline Customer Engagement Strategies, Reducing Call Volumes By Nearly 40%
The pet food supplier saw an immediate drop in the amount of time spent answering…
Accelerate Investor Conference Reveals 2023 Keynote Speakers and Panelists
Lineup Features Gala Keynote Speaker Amy Gilliland, President of General Dynamics Information Technology ARLINGTON, Va.–(BUSINESS…
16 Leading Technology and Service Providers Launch Industry’s First SASE Product and Services Certification
MEF and CyberRatings kick-off beta program of the SASE certification designed to increase market confidence in…
16 Leading Technology and Service Providers Launch Industry’s First SASE Product and Services Certification
MEF and CyberRatings kick-off beta program of the SASE certification designed to increase market confidence in…
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
Figure 2: Systolic Blood Pressure (SBP) Mean change from baseline in SBP vs time. (A)…
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
Figure 2: Systolic Blood Pressure (SBP) Mean change from baseline in SBP vs time. (A)…
Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company
PALO ALTO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company
PALO ALTO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) — NeuroSigma today announced approval of the Monarch…
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) — NeuroSigma today announced approval of the Monarch…
Yield10 Bioscience Completes Harvest of a Majority of the 2023 Winter and Spring Camelina Grain Grown Under Contract, Generating Revenue from Biofuel Production
Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform WOBURN, Mass., Oct. 03, 2023…
Yield10 Bioscience Completes Harvest of a Majority of the 2023 Winter and Spring Camelina Grain Grown Under Contract, Generating Revenue from Biofuel Production
Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform WOBURN, Mass., Oct. 03, 2023…
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of…
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of…
ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) — Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the…
ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) — Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the…
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of…
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of…
Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers
WATERTOWN, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical…